Galantamine: A new acetylcholinesterase inhibitor for the treatment of Alzheimer's disease

P and T

Volumn 27, Issue 3, 2002, Pages 135-138

  Maltz, Martin S ^a   Kirschenbaum, Harold L ^a  

^a New Utrecht Pharmacy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; CIMETIDINE; DONEPEZIL; ERYTHROMYCIN; FLUOXETINE; GALANTAMINE; KETOCONAZOLE; PAROXETINE; QUINIDINE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; GASTRITIS; HEART FAILURE; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPOTENSION; LIVER METABOLISM; MICTURITION DISORDER; PATHOGENESIS; REVIEW; SENILE PLAQUE; VERTIGO;

EID: 0036126998     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Treatment of Alzheimer's disease
2. Diagnosis, Management, and treatment of Alzheimer's disease
3. The Cholinergic hypothesis of Alzheimer's disease: A review of progress
4. Prevalence of Alzheimer's disease in a community population of older persons
5. Age-specific incidence of Alzheimer's disease in a community population
6. Cholinesterase inhibitors: A therapeutic strategy for Alzheimer's disease
7. A 52-week study of the efficacy of rivastigmine in patients with mild to moderate severe Alzheimer's disease
8. A 1-year, randomized, placebo controlled study of donepezil in patients with mild to moderate Alzheimer's disease
9. A controlled trial of tacrine in Alzheimer's disease: The Tacrine Study Group
10. Acetylcholinesterase Inhibitors for Alzheimer's disease
11. Cholinesterase inhibitors for Alzheimer's disease
12. Pharmacokinetic Profile of current therapies for Alzheimer's disease: Implications for switching to galantamine
13. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: Effects on the course of Alzheimer's disease
14. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzhelmer's disease
15. Galantamine is an allosterically potentiating ligand of the human a4/b2n AChR
16. Pharmacokinetics of galantamine in humans and corresponding cholinesterase inhibitors
17. The O-demethylation of the antidementia drug galantamine is catalyzed by cytochrome P4502D6
18. Effects of a flexible galantamine dose in Alzheimer's disease: A randomized, controlled trial
19. Galantamine: A randomized, double-blind, dose comparison in patients with Alzheimer's disease
20. Galantamine in Alzheimer's Disease: A 6-month randomized, placebo-controlled trial with a 6-month extension
21. Solomon PR A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer's disease
22. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomized controlled trial
23. Tacrine for Alzheimer's disease: Cost and benefits
24. The economic impact of tacrine in the treatment of Alzheimer's disease
25. Economic considerations in the treatment and management of Alzheimer's Disease